Kim Jinyoung, Lim Jong-Woo, Kim Hyun-Ouk, Park Joowon, Jeong Eunji, Park Chaewon, Park Geunseon, Yeom Minjoo, Song Daesub, Lim Eun-Kyung, Haam Seungjoo
Department of Chemical and Biomolecular Engineering, Yonsei University, Yonsei-ro 50, Seoul, 120-749, Republic of Korea; Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea.
Department of Virology, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.
Biosens Bioelectron. 2025 Nov 1;287:117762. doi: 10.1016/j.bios.2025.117762. Epub 2025 Jul 7.
The rapid evolution of viruses poses a significant threat to global health, as evidenced by recent pandemics. Umifenovir (Arbidol®), a broad-spectrum antiviral drug, has demonstrated potential in treating various viral infections. This study aimed to assess the antiviral mechanism of umifenovir against influenza A virus (IAV), specifically its interaction with hemagglutinin (HA), using umifenovir-modified gold nanoparticles (umi-GNPs). Umi-GNPs have been applied to various IAV subtypes, including H1N1, H3N2, H4N6, H6N8, and H9N2. Our results demonstrate that umifenovir effectively inhibits viral replication in all tested subtypes at a viral titer of 10 50 % egg infective dose (EID)/mL. Additionally, the aggregation of umi-GNPs with viruses pre-bound to umifenovir was suppressed, indicating that umi-GNPs bind to a specific region of the viral protein. These findings indicate that umi-GNPs can serve as novel agents for visually determining umifenovir resistance in IAV.
病毒的快速进化对全球健康构成了重大威胁，近期的大流行就是明证。广谱抗病毒药物乌米芬诺（Arbidol®）已显示出治疗各种病毒感染的潜力。本研究旨在使用乌米芬诺修饰的金纳米颗粒（umi-GNPs）评估乌米芬诺抗甲型流感病毒（IAV）的抗病毒机制，特别是其与血凝素（HA）的相互作用。Umi-GNPs已应用于多种IAV亚型，包括H1N1、H3N2、H4N6、H6N8和H9N2。我们的结果表明，在病毒滴度为1050%鸡胚感染剂量（EID）/mL时，乌米芬诺能有效抑制所有测试亚型中的病毒复制。此外，umi-GNPs与预先结合了乌米芬诺的病毒的聚集受到抑制，这表明umi-GNPs与病毒蛋白的特定区域结合。这些发现表明，umi-GNPs可作为在IAV中视觉检测乌米芬诺耐药性的新型试剂。
